Adaptive infusion of a glucagon-like peptide-1/glucagon receptor co-agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial.
David C D HopeSaleem AnsariSirazum ChoudhuryKleopatra AlexiadouYasmin TabbakhIbiyemi IlesanmiKatharine LazarusIona DaviesLara Jimenez-PachecoWei YangLaura-Jayne BallReshma MalviyaBeata ReglinskaBernard KhooJames MinnionStephen R BloomTricia Mei-Mei TanPublished in: Diabetes, obesity & metabolism (2024)
An adaptive continuous infusion of the GLP-1/GCGR co-agonist, G3215, is safe and well tolerated offering a unique strategy to control drug exposure. By allowing rapid, response-directed titration, this strategy may allow for mitigation of adverse effects and afford significant weight loss within shorter time horizons than is presently possible with weekly GLP-1R and multi-agonists. These results support ongoing development of G3215 for the treatment of obesity and metabolic disease.
Keyphrases
- weight loss
- bariatric surgery
- roux en y gastric bypass
- gastric bypass
- weight gain
- low dose
- insulin resistance
- metabolic syndrome
- climate change
- glycemic control
- type diabetes
- high fat diet induced
- emergency department
- physical activity
- clinical trial
- adipose tissue
- body mass index
- loop mediated isothermal amplification